Durata Therapeutics to Present Safety and Efficacy Data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Get Alerts DRTX Hot Sheet
Join SI Premium – FREE
CHICAGO, Sept. 3, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq: DRTX) today announced that that it will present seven posters highlighting safety and efficacy data from its recently launched product, DALVANCEā¢ (dalbavancin) for injection, at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), which takes place from September 5-9, 2014 in Washington DC. Copies of the posters will be available on the ICAAC 2014 website as well as on the Durata Therapeutics website.
About DALVANCE (dalbavancin) for injection
DALVANCE is a second generation, semi-synthetic lipoglycopeptide, which consists of a lipophilic side-chain added to an enhanced glycopeptide backbone. DALVANCE is the first and only IV antibiotic approved for the treatment of ABSSSI with a two-dose regimen of 1000 mg followed one week later by 500 mg, each administered over 30 minutes. DALVANCE demonstrates bactericidal activity in vitro against a range of Gram-positive bacteria, such as Staphylococcus aureus (including methicillin-resistant, also known as MRSA, strains) and Streptococcus pyogenes, as well as certain other streptococcal species.
For important prescribing and safety information, see www.dalvance.com.
DALVANCE is a trademark of Durata Therapeutics Holding C.V.
About Durata Therapeutics
Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses.
Forward-looking Statements
Any statements in this press release about Durata's future expectations, plans and prospects constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Durata anticipates that subsequent events and developments will cause its views to change. However, while Durata may elect to update these forward-looking statements at some point in the future, Durata specifically disclaims any obligation to do so.
CONTACT: Allison Wey Durata Therapeutics, Inc. Vice President, Investor Relations and Public Affairs (312) 219-7017 [email protected]Source: Durata Therapeutics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Uwill Honored by EdTech Digest Awards as Best Higher Education Solution
- Digital Twins in Healthcare Market Report Forecast to 2031: Market Size to Grow by US$ 4504.73 million, at a CAGR of 25.97%
- Vitruvi Software Appoints New Leadership, Poised For Accelerated Next Growth Phase
Create E-mail Alert Related Categories
Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!